Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/139143
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMenéndez, Rosario-
dc.contributor.authorEspaña, Pedro P.-
dc.contributor.authorPérez-Trallero, Emilio-
dc.contributor.authorUranga, Ane-
dc.contributor.authorMéndez, Raúl-
dc.contributor.authorCillóniz, Catia-
dc.contributor.authorMarimón, José María-
dc.contributor.authorCifuentes, Isabel-
dc.contributor.authorMéndez, Cristina-
dc.contributor.authorTorres Martí, Antoni-
dc.date.accessioned2019-09-03T17:19:18Z-
dc.date.available2019-09-03T17:19:18Z-
dc.date.issued2017-09-18-
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/2445/139143-
dc.description.abstractBACKGROUND: Streptococcus pneumoniae serotypes distribution in community-acquired pneumonia (CAP) requiring hospitalization in adults after introduction of PCV13 in children is not well known. Our aim was to evaluate the distribution of serotypes in pneumococcal pneumonia according to risk factors and comorbidity conditions after the introduction of PCV13 in children in 2010. METHODS: A prospective study from 2011 to 2014 was performed in immunocompetent adults hospitalized with CAP in 3 Spanish hospitals. Microbiological confirmation was obtained using a serotype specific urinary antigen detection test (UAD test), Binax Now and conventional cultures. RESULTS: 1258 adults were enrolled and pneumococcal pneumonia (invasive disease in 17.7%) was confirmed in 368 (29.3%) and 17.6% of the any-cause CAP were caused by PVC13 serotypes (3.5% PCV7 serotypes). Around 60% of pneumococcal CAP were caused by PCV13 serotypes (74.6% in invasive episodes vs 57.4% in non-invasive ones). The most prevalent serotypes in invasive disease were 1, 3, 7F, 19A and 14. No significant differences were observed in the distribution of PCV13 serotypes across the study periods. Regarding comorbidity, the rate of PCV13 serotypes was similar among them, and it was slightly higher in those with no underlying conditions. CONCLUSIONS: Serotypes included in PCV13 caused a significant proportion of CAP in adults with underlying conditions and in healthy adults, with no significant changes in cases due to PCV7 or PCV13 from 2011 to 2014, suggesting an insufficient indirect protection from childhood vaccination. Strategies for implementing pneumococcal vaccination of adults are encouraged to reduce the incidence of pneumococcal episodes.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.vaccine.2017.08.007-
dc.relation.ispartofVaccine, 2017, vol. 35, num. 39, p. 5264-5270-
dc.relation.urihttps://doi.org/10.1016/j.vaccine.2017.08.007-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.subject.classificationInfeccions per pneumococs-
dc.subject.classificationOrina-
dc.subject.otherPneumococcal Infections-
dc.subject.otherUrine-
dc.titleThe burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec675115-
dc.date.updated2019-09-03T17:19:18Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.idimarina5635481-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
675115.pdf633.82 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons